0001209191-20-055042.txt : 20201016 0001209191-20-055042.hdr.sgml : 20201016 20201016155119 ACCESSION NUMBER: 0001209191-20-055042 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201014 FILED AS OF DATE: 20201016 DATE AS OF CHANGE: 20201016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MARTIN JOHN C CENTRAL INDEX KEY: 0001190578 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39592 FILM NUMBER: 201243952 MAIL ADDRESS: STREET 1: 333 LAKESIDE DRIVE CITY: FOSTER CITY STATE: X1 ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kronos Bio, Inc. CENTRAL INDEX KEY: 0001741830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1300 S. EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN MATEO STATE: CA ZIP: 94402 BUSINESS PHONE: 212-871-7920 MAIL ADDRESS: STREET 1: 1300 S. EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN MATEO STATE: CA ZIP: 94402 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-14 0 0001741830 Kronos Bio, Inc. KRON 0001190578 MARTIN JOHN C C/O KRONOS BIO, INC. 1300 SO. EL CAMINO REAL, SUITE 300 SAN MATEO CA 94402 1 0 0 0 Common Stock 2020-10-14 4 C 0 914333 A 914333 I See footnote Common Stock 2020-10-14 4 C 0 756971 A 1671304 I See footnote Common Stock 2020-10-14 4 C 0 205260 16.15 A 1876564 I See footnote Common Stock 2020-10-14 4 P 0 75800 19.00 A 1952364 I See footnote Series Seed Preferred Stock 2020-10-14 4 C 0 866667 D Common Stock 914333 0 I See footnote Series A Preferred Stock 2020-10-14 4 C 0 717509 D Common Stock 756971 0 I See footnote Convertible Promissory Note 16.15 2020-10-14 4 C 0 3314963.25 0.00 D 2022-02-20 Common Stock 205260 0 I See footnote Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. /s/ David Tanen, Attorney-in-Fact 2020-10-16